세계의 기분부전장애 시장 보고서(2025년)
Dysthymia Global Market Report 2025
상품코드 : 1730838
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,668,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,638,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,609,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

기분부전장애 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 연평균 성장률(CAGR) 9.2%로 성장할 전망이며, 206억 달러로 성장이 예측됩니다. 예측 기간 동안의 성장은 지속성 우울증성 질환 유병률 상승, 인지도 및 진단율 향상, 항우울제 치료의 진보, 디지털 정신건강 솔루션의 채택 확대, 정신건강 치료에 대한 보험 적용범위 확대 등의 요인에 기인할 것으로 보입니다. 예측 기간 주요 동향으로는 AI 활용 정신건강 진단, 맞춤형 의료 및 약리 유전체, 디지털 치료 및 정신건강 앱, 원격 정신의료 및 원격 상담, 사이키델릭을 포함한 신규 항우울제 개발 등이 있습니다.

정신 건강 질환의 유병률 증가는 기분부전장애 시장의 확대를 촉진할 것으로 예측됩니다. 정신 질환이라고도 불리는 정신 건강 질환에는 기분, 사고, 행동에 영향을 미치는 폭넓은 질환이 포함됩니다. 끊임없는 업무 부담, 경제적 부담, 디지털 과다 등이 만성적인 불안으로 이어지는 현대 라이프스타일로 인한 지속적인 스트레스로 인해 정신건강 상태에 시달리는 사람들이 늘고 있습니다. 기분부전장애 치료는 기분을 안정시키고 감정적 회복력을 높이며 전체적인 행복감을 향상시키기 위해 약물요법, 라이프스타일 조정과 같은 장기적인 전략을 제공함으로써 정신건강을 돕습니다. 예를 들면, 미국을 거점으로 하는 단체인 National Alliance on Mental Illness는, 2024년 미국 18-44세 개인의 정신병 스펙트럼 및 기분장애 입원 건수는 연간 약 60만 건에 이르렀다고 보고했습니다.

헬스케어 시설의 성장은 기분부전장애 시장의 성장에 기여할 것으로 기대됩니다. 헬스케어 시설에는 효과적인 헬스케어 서비스를 제공하기 위해 필수불가결한 시스템, 리소스, 물리적 공간이 포함됩니다. 의료 요구가 진화함에 따라 헬스케어 시설의 증가는 진단 및 치료의 진보에 의해 초래되며, 복잡한 건강 상태를 관리하기 위해 업그레이드된 인프라가 필요합니다. 헬스케어 인프라는 의료시설, 훈련받은 전문가, 약제를 환자가 바로 이용할 수 있도록 함으로써 기분부전장애 치료를 돕습니다. 미국 비영리단체인 미국병원협회에 따르면 미국 병원 수는 2024년 6,120개로 2022년 6,093개에서 증가했습니다. 이러한 헬스케어 인프라의 확대는 기분 변조증 시장의 성장을 촉진하는 데 중요한 역할을 하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Dysthymia, also referred to as persistent depressive disorder (PDD), is a chronic form of depression that lasts for at least two years (one year in children and adolescents). It is marked by a consistently low mood that persists for most of the time.

The main treatment options for dysthymia include psychotherapy, pharmacotherapy, and a combination of both. Psychotherapy involves working with a mental health professional to manage and address the condition. The severity of dysthymia can range from mild to moderate to severe, often accompanied by comorbidities such as anxiety disorders, depression, and substance abuse. These treatments are available through various distribution channels, both online and offline, and are utilized by a range of end-users, including hospitals and clinics.

The dysthymia market research report is one of a series of new reports from The Business Research Company that provides dysthymia market statistics, including the dysthymia industry global market size, regional shares, competitors with the dysthymia market share, detailed dysthymia market segments, market trends, and opportunities, and any further data you may need to thrive in the dysthymia industry. This dysthymia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dysthymia market size has grown strongly in recent years. It will grow from $13.25 billion in 2024 to $14.50 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth observed in the historic period can be attributed to factors such as rising awareness of mental health disorders, advancements in antidepressant medications, the increasing prevalence of chronic depression, improved access to healthcare and therapy, and evolving diagnostic criteria in psychiatry.

The dysthymia market size is expected to see strong growth in the next few years. It will grow to $20.60 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth expected during the forecast period can be attributed to factors such as the rising prevalence of persistent depressive disorder, increasing awareness and diagnosis rates, advancements in antidepressant therapies, greater adoption of digital mental health solutions, and expanding insurance coverage for mental health treatments. Key trends in the forecast period include AI-driven mental health diagnostics, personalized medicine and pharmacogenomics, digital therapeutics and mental health apps, telepsychiatry and remote counseling, and the development of novel antidepressant drugs, including psychedelics.

The growing prevalence of mental health disorders is expected to drive the expansion of the dysthymia market. Mental health disorders, also referred to as psychiatric or mental illnesses, include a wide range of conditions that impact mood, thinking, and behavior. People are increasingly suffering from mental health conditions due to ongoing stress from modern lifestyles, where constant work pressures, financial strains, and digital overload lead to chronic anxiety. Dysthymia treatment supports mental health by offering long-term strategies such as therapy, medication, and lifestyle adjustments to stabilize mood, enhance emotional resilience, and improve overall well-being. For example, in 2024, the National Alliance on Mental Illness, a US-based organization, reported that psychosis spectrum and mood disorders account for nearly 600,000 hospitalizations annually among individuals aged 18-44 in the U.S. Thus, the rising prevalence of mental health disorders is fueling the growth of the dysthymia market.

The growth of healthcare facilities is expected to contribute to the growth of the dysthymia market. Healthcare facilities include the essential systems, resources, and physical spaces needed to provide effective healthcare services. As medical needs evolve, the increase in healthcare facilities is driven by advancements in diagnostics and treatments, which require upgraded infrastructure to manage complex health conditions. Healthcare infrastructure supports dysthymia treatment by ensuring that medical facilities, trained professionals, and medication are readily available to patients. According to the American Hospital Association, a US-based non-profit organization, the United States had 6,120 hospitals in 2024, an increase from 6,093 hospitals in 2022. This expansion of healthcare infrastructure is playing a key role in driving the growth of the dysthymia market.

In July 2023, Big Health Inc., a US-based digital health company specializing in mental health technology, acquired Limbix Health Inc. for an undisclosed amount. This acquisition expands Big Health's range of non-drug treatment options, particularly in the area of VR-based therapeutics for mental health conditions such as depression and anxiety. Limbix Health, a US-based digital therapeutics company, uses virtual reality (VR) technology to treat mental health disorders, including dysthymia.

Major players in the dysthymia market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi SA, BristolMyers Squibb Company, AstraZeneca plc, Novartis International AG, Roche Holding AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Biogen Inc., Horizon Therapeutics plc, Shionogi & Co. Ltd., Jazz Pharmaceuticals, Ipsen SA, Cipla Limited, Lupin Pharmaceuticals, Mallinckrodt Pharmaceuticals.

North America was the largest region in the dysthymia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dysthymia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dysthymia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dysthymia market consists of revenues earned by entities by providing treatment such as mindfulness-based therapy, interpersonal therapy (IPT), and cognitive behavioral therapy (CBT). The market value includes the value of related goods sold by the service provider or included within the service offering. The dysthymia market also includes sales of antidepressant medications, psychotherapy tools, digital therapeutics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dysthymia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dysthymia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for dysthymia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dysthymia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Dysthymia Market Characteristics

3. Dysthymia Market Trends And Strategies

4. Dysthymia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Dysthymia Growth Analysis And Strategic Analysis Framework

6. Dysthymia Market Segmentation

7. Dysthymia Market Regional And Country Analysis

8. Asia-Pacific Dysthymia Market

9. China Dysthymia Market

10. India Dysthymia Market

11. Japan Dysthymia Market

12. Australia Dysthymia Market

13. Indonesia Dysthymia Market

14. South Korea Dysthymia Market

15. Western Europe Dysthymia Market

16. UK Dysthymia Market

17. Germany Dysthymia Market

18. France Dysthymia Market

19. Italy Dysthymia Market

20. Spain Dysthymia Market

21. Eastern Europe Dysthymia Market

22. Russia Dysthymia Market

23. North America Dysthymia Market

24. USA Dysthymia Market

25. Canada Dysthymia Market

26. South America Dysthymia Market

27. Brazil Dysthymia Market

28. Middle East Dysthymia Market

29. Africa Dysthymia Market

30. Dysthymia Market Competitive Landscape And Company Profiles

31. Dysthymia Market Other Major And Innovative Companies

32. Global Dysthymia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dysthymia Market

34. Recent Developments In The Dysthymia Market

35. Dysthymia Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기